BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/21/2015 5:04:00 PM | Browse: 2037 | Download: 1437
 |
Received |
|
2014-07-15 09:46 |
|
Peer-Review Started |
|
2014-07-15 15:36 |
|
To Make the First Decision |
|
2014-10-28 14:23 |
|
Return for Revision |
|
2014-11-03 09:01 |
|
Revised |
|
2014-12-01 00:22 |
|
Second Decision |
|
2014-12-23 20:18 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2014-12-31 13:30 |
|
Articles in Press |
|
2014-12-31 13:30 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2015-01-12 13:31 |
|
Publish the Manuscript Online |
|
2015-01-21 17:04 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Case Control Study |
| Article Title |
End-organ protection in hypertension by the novel and selective Rho-kinase inhibitor, SAR407899
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Matthias Löhn, Oliver Plettenburg, Aimo Kannt, Markus Kohlmann, Armin Hofmeister, Dieter Kadereit, Peter Monecke, Alexander Schiffer, Anke Schulte, Hartmut Ruetten and Yuri Ivashchenko |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Dr. Matthias Löhn, Translational Medicine, Sanofi-Aventis, Industriepark Hoechst, 65926 Frankfurt am Main, Germany. matthias.loehn@sanofi.com
|
| Key Words |
Hypertension; End organ damage; Rho-kinase; Angiotensin converting enzyme-inhibition |
| Core Tip |
Rho-kinase (ROCK) is considered an important ta-rget in cardiovascular diseases, e.g., hypertension and nephropathy. Currently available treatment only moderately alleviates the progression of chronic kidney diseases. We have identified a novel, potent and selective inhibitor of ROCK (SAR407899) and characterized its effects in vivo. The therapeutic efficacy of SAR407899 has been compared to the current standard treatment for hypertension in two animal models of hypertension, one of which is sensitive and the other insensitive (deoxycorticosterone acetate) to angiotensin converting enzyme-inhibition. ROCK-inhibition by SAR407899 may represent a new therapeutic option either as a monotherapy or in combination with existing modern therapeutics for the treatment of hypertension and its complications. |
| Publish Date |
2015-01-21 17:04 |
| Citation |
Löhn M, Plettenburg O, Kannt A, Kohlmann M, Hofmeister A, Kadereit D, Monecke P, Schiffer A, Schulte A, Ruetten H, Ivashchenko Y. End-organ protection in hypertension by the novel and selective Rho-kinase inhibitor, SAR407899. World J Cardiol 2015; 7(1): 31-42 |
| URL |
http://www.wjgnet.com/1949-8462/full/v7/i1/31.htm |
| DOI |
http://dx.doi.org/10.4330/wjc.v7.i1.31 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
